Paternal exposure to ribavirin: Pregnancy and neonatal outcome

Antiviral Therapy

Volumn 8, Issue 1, 2003, Pages 73-75

  De Santis, Marco ^a   Carducci, Brigida ^a   Cavaliere, Anna Franca ^a   De Santis, Lidia ^a   Lucchese, Angela ^a   Straface, Gianluca ^a   Caruso, Alessandro ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; RIBAVIRIN;

ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; DOSE TIME EFFECT RELATION; EMBRYOTOXICITY; FATHER; FETUS DEVELOPMENT; FOLLOW UP; GESTATIONAL AGE; HEPATITIS C; HUMAN; INTERVIEW; NEWBORN; OUTCOMES RESEARCH; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; SEXUAL BEHAVIOR; SPONTANEOUS ABORTION; TERATOGENICITY; VIRUS HEPATITIS;

ABNORMALITIES, DRUG-INDUCED; ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FETUS; HEPATITIS C, CHRONIC; HUMANS; INFANT, NEWBORN; INTERFERONS; MALE; PATERNAL EXPOSURE; PREGNANCY; PREGNANCY OUTCOME; RIBAVIRIN;

EID: 0037299350     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Ferm VH, Willhite C & Kilham L. Teratogenic effects of ribavirin on hamster and rat embryos. Teratology 1978; 17:93-102.
2. Hillyard IW. The preclinical toxicology and safety of ribavirin. In: Ribavirin: a Broad Spectrum Antiviral Agent. Edited by RA Smith & W Kirkpatrick 1980; pp 59-72. New York: Academic Press.
3. Kilham L & Ferm VH. Congenital anomalies induced in hamster embryos with ribavirin. Science 1977; 195:413-414.
4. Johnson EM. The effects of ribavirin on development and reproduction: a critical review of published and unpublished studies in experimental animals. Journal of American College of Toxicology 1990; 9(5):551-561.
5. Kochhar DM, Penner JD & Knudsen TB. Embryotoxic, teratogenic, and metabolic effects of ribavirin in mice. Toxicology & Applied Pharmacology 1980; 52:99-112
6. REBETOL® Product information. Available on http://www.hepatitisinnovation.com/pro/rebetol
7. Atmar RL, Englund JA & Hammill H. Complications of measles during pregnancy. Clinical Infectious Diseases 1992; 14:217-226.
8. Hegenbarth K, Maurer U, Kroisel PM, Fickert P, Trauner M & Stauber RE. No evidence for mutagenic effects of ribavirin: report of two normal pregnancies. The American Journal of Gastroenterology 2001; 96(7):2286-2287 [Letter].
9. Maddrey WC. Safety of combination interferon a2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. Seminars in Liver Disease 1999; 19(1):67-75.
10. Mishkin D & Deschenes M. Conception soon after discontinuing interferon/ribavirin therapy: a successful outcome. The American Journal of Gastroenterology 2001; 96(7):2285-2286 [Letter].
11. Grasso G & Muscettola M. Possible role of interferon-g in ovarian function. Annals of the New York Academy of Sciences 1992; 650:191-196.
12. Pons JC, Lebon P, Frydman R & Delfraissy JF. Pharmacokinetics of interferon-α in pregnant women and fetoplacental passage. Fetal Diagnosis & Therapy 1995; 10:7-10.
13. Geyman JP, Oliver LM & Sullivan SD. Expectant, medical, or surgical treatment of spontaneous abortion in first trimester of pregnancy? A pooled quantitative literature evaluation. Journal of American Board Family Practice 1999; 12(1):55-64.